TMB: a new piece of the NSCLC-treatment puzzle

Tumor mutational burden is since October 2018 NCCN’s (National Comprehensive Cancer Network) newest and most recommended biomarker for selecting checkpoint-inhibitor Immunotherapy in Non-Small Cell Lung Cancer. Immunotherapy is often regarded as the promising cancer-cure solution and has undergone drastic investigations and improvement in last time. Tumor mutational burden comes as a novel result of the necessity of establishing emerging biomarkers […]